Molecular Partners Analyst Ratings
Molecular Partners Analyst Ratings
While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a downgraded with a price target of $30.00 to $8.00. The current price Molecular Partners (MOLN) is trading at is $6.25, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/29/2022 | 28% | SVB Leerink | $30 → $8 | Downgrades | Outperform → Market Perform |
| 05/25/2022 | — | Credit Suisse | Upgrades | Underperform → Neutral | |
| 04/27/2022 | 364% | SVB Leerink | $42 → $29 | Maintains | Outperform |
| 01/14/2022 | 572% | SVB Leerink | $35 → $42 | Maintains | Outperform |
| 08/27/2021 | 460% | SVB Leerink | $36 → $35 | Maintains | Outperform |
| 07/13/2021 | 700% | Cowen & Co. | → $50 | Initiates Coverage On | → Outperform |
| 06/21/2021 | 300% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/29/2022 | 28% | SVB Leerink | 30 美元 → 8 美元 | 降級 | 跑贏大盤 → 市場表現 |
| 05/25/2022 | — | 瑞士信貸 | 升級 | 表現不佳 → 中性 | |
| 04/27/2022 | 364% | SVB Leerink | 42 美元 → 29 美元 | 維持 | 跑贏大盤 |
| 2022 年 1 月 14 日 | 572% | SVB Leerink | 35 美元 → 42 美元 | 維持 | 跑贏大盤 |
| 08/27/2021 | 460% | SVB Leerink | 36 美元 → 35 美元 | 維持 | 跑贏大盤 |
| 2021 年 7 月 13 日 | 700% | Cowen & Co. | → 50 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 06/21/2021 | 300% | HC Wainwright & Co. | → 25 美元 | 假設 | → 購買 |
Molecular Partners Questions & Answers
分子夥伴問題與解答
The latest price target for Molecular Partners (NASDAQ: MOLN) was reported by SVB Leerink on August 29, 2022. The analyst firm set a price target for $8.00 expecting MOLN to rise to within 12 months (a possible 28.00% upside). 4 analyst firms have reported ratings in the last year.
SVB Leerink於2022年8月29日公佈了分子合作伙伴（納斯達克股票代碼：MOLN）的最新目標股價。該分析公司將目標股價設定爲8.00美元，預計MOLN將在12個月內上漲至8.00美元（可能上漲28.00％）。去年有4家分析公司公佈了評級。
The latest analyst rating for Molecular Partners (NASDAQ: MOLN) was provided by SVB Leerink, and Molecular Partners downgraded their market perform rating.
分子合夥人（納斯達克股票代碼：MOLN）的最新分析師評級由SVB Leerink提供，Molecular Partners下調了其市場表現評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Partners was filed on August 29, 2022 so you should expect the next rating to be made available sometime around August 29, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Molecular Partners的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Molecular Partners的最後一次評級是在2022年8月29日提交的，因此您應該預計下一個評級將在2023年8月29日左右公佈。
While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a downgraded with a price target of $30.00 to $8.00. The current price Molecular Partners (MOLN) is trading at is $6.25, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的分子合作伙伴（MOLN）評級下調，目標股價爲30.00美元至8.00美元。Molecular Partners（MOLN）目前的交易價格爲6.25美元，超出了分析師的預測區間。
